VRELysin

AXP000227.1 · Phage therapy

Platform
phage cocktail (non-engineered)
Originator
Intralytix
Sponsor
Intralytix

Names

NameTypeSource
VRELysinpreferred name, codecurator, ctgov

Virus

Role
Phage
Family
Caudoviricetes
Virus
Enterococcus bacteriophage (cocktail)
Replication
replicating
Route
oral
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05715619Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized SubjectsSuspendedPhase 1/22023-10-252026-10-3180Vancomycin-Resistant Enterococcal Colonization

Recent changes

No changes recorded in its trials yet.

Notes

Oral phage cocktail against vancomycin-resistant Enterococcus, in healthy and VRE-colonised subjects (phase 1/2a NCT05715619, suspended).

How to cite

VRELysin (AXP000227.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000227.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.